Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Algernon Pharmaceuticals Inc Class A (AGN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
0.105 -0.025    -19.23%
29/04 - Closed. Currency in CAD ( Disclaimer )
Type:  Equity
Market:  Canada
  • Volume: 50,250
  • Bid/Ask: 0.100 / 0.120
  • Day's Range: 0.105 - 0.125
Algernon Pharma 0.105 -0.025 -19.23%

AGN Ex Dividend Date, Yield & History

 
Get details on the Algernon Pharma stock dividend history and find the AGN ex-dividend date. View also the dividend payment date and dividend yield.
InvestingPro Dividend Insights
Ex-Dividend Date Dividend Type Payment Date Yield
Mar 28, 2023 Mar 28, 2023 -
Legend
Monthly
Quarterly
Semi-Annual
Annual
Trailing Twelve Months
Other
Interim
Final
Bonus
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced dividend insights and history for in-depth analysis of historical dividend payouts and performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

AGN Comments

Write your thoughts about Algernon Pharmaceuticals Inc Class A
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mike Powell
Mike Powell May 26, 2023 2:59PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Significant progress has been made in their drug development while they've also secured additional funding. Recent news of Notice of Allowance from USPTO and successful rights offering only further validate their business model of repurposing drugs and protecting IP.
Reply
0 0
Report
Mike Powell
Mike Powell Apr 21, 2023 11:34AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Recent news that AGN's received notice of allowance for NP-251 (Repirinast) as a promising candidate treating CKD and fatty liver disease is pretty interesting, adding another strong candidate in treating chronic diseases with unmet needs. Furthermore, preclinical studies are showing its a strong candidate for treatment.
Reply
0 0
Report
Mike Powell
Mike Powell Apr 13, 2023 1:48PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Latest results from the phase 1 study of DMT for stroke patients is making solid progress with results from their 2nd cohort successfully dosed without any issues - 3rd cohort is receiving higher doses with the purpose of determining if hitting "Sigma 1" receptor with DMT can create enough brain derived neurotrophic factor to aid in healing process for stroke patients.
Reply
0 0
Report
Harrison Joel
Harrison Joel Apr 06, 2023 1:51PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Good to hear that they've dosed the 2nd round of patients in the DMT Phase 1 trial. With nearly 800,000 people each year experiencing a stroke in the US alone, this provides a huge market opportunity and can be a life-changing form of treatment for many. So definitely keep tabs on development as research continues on the treatment.
Reply
0 0
Report
Harrison Joel
Harrison Joel Feb 16, 2023 2:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
DMT for stoke has been found safe to proceed to the next phase, now they're focusing on identifying the correct dosage amount for the best recovery effect. DMT could be a revolutionary drug in the space and could further legitimize psychedelics in healthcare as a whole.
Reply
0 0
Report
Mike Powell
Mike Powell Jan 24, 2023 3:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Algernon announces they’ve dosed the first subject in the Phase 1 DMT clinical stroke study. This study is being conducted at the Centre for Human Drug Research in Leiden, Netherlands. The first part of this study will use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects. AGN’s DMT trial also positions them as one of the cheapest psychedelic stocks on the market
Reply
0 0
Report
Harrison Joel
Harrison Joel Jan 18, 2023 2:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The DMT study makes AGN the first company to begin investigating its effects on stroke! Will be interesting to see the results as they continue with phase 1 and move into phase 2 later on.
Reply
0 0
Report
Mike Powell
Mike Powell Jan 13, 2023 2:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The appointment of Dr. Peter Dicpinigaitis MD as a medical consultant to Algernon Pharmaceuticals' chronic cough research program is pretty significant. Dr. Dicpinigaitis is the founder and director of the Montefiore Cough Center, one of the few specialty centers in the world exclusively committed to the evaluation and management of patients with chronic cough. He’s authored many peer-reviewed journal articles and book chapters on cough and is considered an authority on the performance of cough challenge studies in clinical research. He also serves as the Editor-in-Chief of the journal LUNG. His expertise will be valuable to the company as they advance towards their upcoming Phase 2b chronic cough study of NP-120 (Ifenprodil).
Reply
1 0
Report
Mike Powell
Mike Powell Jan 12, 2023 1:27PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Is Ifenprodil the next billion dollar cough drug? Algernon Pharmaceuticals recently received FDA Orphan Drug Designation for Ifenprodil in IPF treatment & CEO Christopher Moreau shares an update for a new Phase 2B study slated to commence in July 2023 which will determine if its superior to current cough treatments.
Reply
0 0
Report
Mike Powell
Mike Powell Dec 06, 2022 1:34PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Catalyst alert with Algernon’s recent news that they’ve been granted orphan drug designation by the FDA for its use of Ifenprodil as a treatment for IPF. FDA orphan drug designation is massive due to the potential 7-year exclusivity following approval. Prices have climbed ~22%+ on the day of this news, more to come as they progress through the next steps of their clinical program.
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email